Oxford Biomedica plc (LON:OXB) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Oxford Biomedica plc (LON:OXB) have received an average recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is GBX 600.04.

OXB has been the subject of several research analyst reports. Stifel Nicolaus reaffirmed a “buy” rating and set a GBX 950 target price on shares of Oxford Biomedica in a research report on Wednesday, March 11th. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 8.27 target price on shares of Oxford Biomedica in a research report on Tuesday, June 2nd. Finally, Royal Bank Of Canada decreased their target price on Oxford Biomedica from GBX 1,170 to GBX 1,140 and set an “outperform” rating for the company in a research report on Wednesday.

Oxford Biomedica Price Performance

Shares of LON:OXB opened at GBX 620 on Friday. The company has a current ratio of 2.20, a quick ratio of 1.67 and a debt-to-equity ratio of 162.16. The stock’s fifty day simple moving average is GBX 615.72 and its two-hundred day simple moving average is GBX 663.17. Oxford Biomedica has a 1-year low of GBX 306.50 and a 1-year high of GBX 952. The stock has a market cap of £750.26 million, a PE ratio of -23.03 and a beta of 1.10.

Oxford Biomedica (LON:OXB) last announced its earnings results on Thursday, March 26th. The biopharmaceutical company reported GBX (26.92) earnings per share (EPS) for the quarter. Oxford Biomedica had a negative net margin of 17.85% and a negative return on equity of 48.56%. As a group, analysts forecast that Oxford Biomedica will post -31.0799998 EPS for the current fiscal year.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.